Consumer groups call for condemnation of ACTA independent of ECJ

27 March 2012

Health-related consumer groups Health Action International (HAI) Europe, Oxfam, Medecins Sans Frontieres (MSF) and the Trans Atlantic Consumer Dialogue (TACD) have issued a call for European Union parliamentarians to condemn the Anti-Counterfeiting Trade Agreement ( ACTA) independently of the European Court of Justice (ECJ) referral.

On February 22, the European Commission announced its intent to ask the ECJ for an opinion on the conformity of the Anti-Counterfeiting Trade Agreement with fundamental freedoms. Having denied the need for any legal or impact assessment before, the Commission has resorted to this referral in an attempt to deflect growing protests and avoid ACTA being definitively rejected by national governments and the European Parliament.

The ECJ referral will only assess ACTA’s compatibility with EU Treaty law and not with obligations under international agreements in relation to access to medicines, the consumer groups contend. This limited legal assessment under the ECJ referral does not assess fundamental political questions the ACTA raises for its lack of accountability and transparency, the bypassing of multilateral forums, and its impact on access to medicines. These concerns remain, whatever the outcome of the ECJ test, and policy makers should act on these concerns.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics